BioSpace News Archive

Drug Development

Nectin’s Series A Hits $25M as Investors Support New Target for Solid Tumors

Nectin Therapeutics announced dosing of the first solid tumor patient in a Phase I clinical trial while additional investors jumped in to expand the company’s Series A to just over $25 million.

November 30, 2022
·
3 min read
·
Kate Goodwin
Drug Development

After a Tough Summer, X4 Celebrates Phase III Win in WHIM Syndrome (Updated)

Four months after implementing a restructuring initiative to extend cash flow, X4 Pharmaceuticals is celebrating positive top-line results in WHIM syndrome.

November 30, 2022
·
3 min read
·
Kate Goodwin
Drug Development

Eisai & Biogen Address Lecanemab’s Safety Concerns at CTAD

Full data from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.

November 30, 2022
·
3 min read
·
Tristan Manalac
Drug Development

With Positive Phase II Data, Nimbus’ Psoriasis Therapeutic Poised to Challenge BMS

Nimbus reported positive Phase IIb results for NDI-034858 in moderate-to-severe plaque psoriasis, which researchers hope will have the efficacy of JAK inhibitors without the safety issues.

November 30, 2022
·
2 min read
·
Mark Terry
Career Advice

A Guide to Becoming a Clinical Research Nurse

The role of a clinical research nurse can be rewarding, but it’s not without challenges. Find out more about the role of a clinical research nurse and what it takes to become one in our guide.

November 30, 2022
·
4 min read
·
Christie Adams
Drug Development

CTAD 2022: Pivotal Anti-Amyloid Data and New Pathways (Updated)

BioSpace sat down with Roche Global Head of Neurodegeneration Rachelle Doody, Ph.D. and Alzheimer’s Drug Discovery Foundation Co-founder Howard Fillit, M.D. to discuss the highlights.

November 30, 2022
·
6 min read
·
Heather McKenzie
Business

Horizon Therapeutics Becomes Target of Acquisition By Pharma Giants

Shares of Horizon Therapeutics are soaring in premarket trading Wednesday after the rare disease company confirmed it is being courted for a potential acquisition by three pharma giants.

November 30, 2022
·
2 min read
·
Alex Keown
Deals

argenx Enters Into Agreement To Acquire Priority Review Voucher

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced an agreement to acquire a U.S. Food and Drug Administration Priority Review Voucher for $102 million.

November 30, 2022
·
3 min read
New Prospective Study Finds That Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring Can Help Provide Effective Blood Management in Patients Undergoing Major Surgery

Masimo announced the findings of a prospective, double-blinded, randomized, controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan.

November 30, 2022
·
11 min read
Centers for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia’s IMMray PanCan-d test

Immunovia announced that the Centers for Medicare and Medicaid Services has finalized their payment determination on a price of $897 for Immunovia’s IMMray PanCan-d test.

November 30, 2022
·
2 min read